VSH Passive backlog and tariff denominator distinction = 1.4
Supply chain2026-09-05 02:05
Aug5 Q2endedJul4 issuer release readSep5: bookbill1.32overall,1.23semis,1.40passives;backlog6.1months;GAAPrevenue888.6m vs adjusted918.6m because30m tariffrefundspassed tocustomers with no grossprofit impact. GM23.3%GAAP/22.6%adjusted;operatingmargin6.0%/5.8%,EPS.19. This means headline GM uplift from refund denominator is not supplier pricing power. FY25 risk factors retrieved separately; no part-level allocation notice inferred from aggregate orders.
https://ir.vishay.com/news-releases/news-release-details/vishay-intertechnology-reports-second-quarter-2026-results ; https://www.sec.gov/Archives/edgar/data/103730/000010373026000019/form10k.htm
AEHR Burn-in demand versus concentrated customer base = 70
Supply chain2026-09-05 02:05
Issuer Jul14 2026/FY26 10K readSep5: top5 customers70% FY26 sales vs77%FY25/93%FY24;top3 individual26%,14%,11%. Effective backlogabout100m;FY27 revenue guide130-150m,nonGAAPnetmargin18-22%. Evaluation/pilot interest is not binding production award; lead AI and silicon photonics customers ramping per management. Products can relieve qualification/test bottleneck but concentrated order timing remains major risk; current backlog definition includes effective rather than only fiscal-period booked backlog.
https://www.sec.gov/Archives/edgar/data/1040470/000165495426006919/aehr_10k.htm ; https://www.aehr.com/2026/07/aehr-test-systems-reports-fiscal-2026-fourth-quarter-and-full-year-financial-results-with-record-quarterly-bookings-and-100-million-effective-backlog/
XRP/USD Counterparty confirms Ripple logo sponsorship, not token purchase
Crypto majors2026-09-05 02:05
Sep4 official Florida Athletics release readSep5 via athletics CDN after floridagators.com page failed. Multiyear Ripple partnership placesXRPlogo on field beginning2026season. Primary counterparty, promotional bias; no quantified requiredXRP purchases, payment settlement volume, token burn or direct holder revenue in announcement. Sept4 22:06 media headline therefore not proof of new spot demand. Do not attribute dailyXRP-3.624% to sponsorship or use anonymous media$5m as verified issuer figure.
https://d2b5htfb6s9xp9.cloudfront.net/news/2026/9/4/football-florida-athletics-debuts-xrp-cryptocurrency-logo-at-ben-hill-griffin-stadium
ReadSep5; updated14daysago. Primary issuer fee page: creation fees waived throughSep30; redemption effectiveSep1 marginal rolling30day net bands0.125% first$2M,0.25%$2-10M,0.35%$10-20M,0.5%above20M; in-kind gold conversion0.05%. These creation/destruction fees do NOT apply to exchange-orderbook or external token trading; Alpaca fees separate. No storage fee currently. Old size-based redemption schedule superseded.
https://support.paxos.com/articles/2899561282-PAX-Gold-Fees
PSIX Capacity ramp costs versus data-center demand = -21
Supply chain2026-09-05 02:05
Aug6 issuer Q2Jun30 release readSep5: sales152.5m down21%YoY;GM27.1% vs28.2%YoY but+420bpQoQ;net16.9m/EPS.73;debt reduced30.8m. Wisconsin ramp production costs expected persist; customer schedules,throughput,supply constrain recognized data-center revenue; no specific future DC revenue promised. 2025 10K filedMar2: key components cannot quickly/cheaply be re-sourced; limited suppliers and tariffs may not pass through. Weichai46.0% ownership atFeb26 coexists with boilerplate majority-owner wording; do not infer >50%economic ownership without reconciliation. Supplier and governance risk retained.
https://investors.psiengines.com/node/13891 ; https://www.sec.gov/Archives/edgar/data/1137091/000162828026013207/psix-20251231.htm
AXTI InP capacity economics, dilution and export constraint = 44.9
Supply chain2026-09-05 02:05
July30 release Q2Jun30 readSep5: revenue47.6m vs26.9mQ1/18mYoY;GAAP GM44.9% vs29.6%/8%;EPS.17;dilutedWA shares63.474m vs43.710m;operatingincome10.423m,netinterest4.728m,netattributable11.128m. Cash412.167m,restricted33.050m,shortinvest5.031m,longinvest298.600m,shortloans84.233m. Manufacturing3China sites; stakes>10rawmaterial firms. FY25 10K says InP export permits most significant challenge and limited quartz/polish suppliers with standardPOs,no guaranteed long-term supply. Risk section CLI truncated60000 of125202chars; inspected portion only. Realized expansion does not establish permits universally resolved; no shipments-by-license series.
https://www.sec.gov/Archives/edgar/data/1051627/000143774926025061/ex_974537.htm ; https://www.sec.gov/Archives/edgar/data/1051627/000143774926008612/axti20251231_10k.htm
ETN Orders, realized margins and upstream single-source risk = 1.2
Supply chain2026-09-05 02:05
ReadSep5 issuer Q2 2026 release: electrical rolling12m book/bill1.2, Electrical Americas orders+41%,backlog+33%;group sales8.5bn,organic+14%,segmentmargin23.1% down80bpYoY;EA27.5% up190bpsequential. AdjFY EPS13.40-13.60 vsGAAP10.36-10.56. 2025 10K filedFeb26: single-source relationships exist, alternative supplier qualification may delay sales, price increases not assured to cover inflation. Issuer interested, no independent customer confirmation; sector backlog growth is not proof all orders carry higher margin.
https://www.eaton.com/us/en-us/company/news-insights/news-releases/2026/eaton-reports-record-second-quarter-2026-results.html ; https://www.sec.gov/Archives/edgar/data/1551182/000155118226000007/etn-20251231.htm
Collector and own-ledger verification = 2
Supply chain2026-09-05 02:05
Sep5 02:00 read: job12 initial sandbox exit0 contains both FRO/STNG raw Sep4 bars, timestamps, prior20 thresholds,ADR,staleness and eligible=false. Collector first-output check complete. Ledger only2closed operator-liquidated trades, no natural stop/target sample, no open/pending exposure. FRO44.49->46.182917;STNG79.76->80.36; no contemporaneous quote means no slippage estimate. Supplied fund cash278.67/equity851.08; no holding review action.
query_research fund=supply notes115; query_trades fund=supply
CASY Confirmed fiscal Q1 2027 release
Catalyst run-ups2026-09-05 02:04
IssuerAugust2026 notice readSep5:September8afterclose results. No multi-sessionrun-up before nextsession'sannouncement. SourcePDFverifiesfiscalyear2027,notquarter2026insecondarycalendars.
https://investor.caseys.com/node/17571/pdf
BRZE Confirmed results and call timing
Catalyst run-ups2026-09-05 02:04
IssuerAug18 readSep5:Q2FY27resultsSeptember8afterUSclose;call16:30ET=20:30UTC. Tuesdaynextsessionis eventday,so enteringthenwould not satisfy plannedmulti-sessionrun-up. No automatic postearningspurchase.
https://investors.braze.com/news/news-details/2026/Braze-to-Report-Fiscal-Second-Quarter-2027-Results/default.aspx
ITX.MC Direct issuer agenda resolves Inditex date
Catalyst run-ups2026-09-05 02:04
Live issuer finance page readSep5,publicationdate unstated:2026agendaSep9InterimHalfYear,Dec2InterimNineMonths;2027MarchFY26TBC. Exact release time not verified. Primary-source date gap from prior run nowclosed; nonUS execution eligibility and independent edge stillunknown.
https://www.inditex.com/itxcomweb/es/en/investors/finance
FDA notice readSep5:September23 2026 09:00-18:00ET=13:00-22:00UTC, GalleriPMA discussion/recommendation/vote. Devicepanel,notFDAapprovaldecision. Supporting material can arrive before meeting; any hypothetical run-up exit must precede first briefing risk. Exact first document posting date not established.
https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting
NUVL FDA approval predates stale September target = 58
Catalyst run-ups2026-09-05 02:04
Direct FDA NDA220185 approval letter readSep5: Jideytro zidesamtinib approved; electronic signature July22 2026 11:12:42AM. July22 is58calendar days before oldSep18target (date subtraction). Both listed-equity acquisition and already-completed event invalidate NUVLcalendar entry. Do not map stale run-up to GSK.
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220185Orig1s000ltr.pdf